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Endothelial Progenitor Cell-Derived
Factors Exert Neuroprotection in Cultured
Cortical Neuronal Progenitor Cells
Stefano Di Santo1,2 , Stefanie Seiler1, Raphael Guzman2,*,
and Hans Rudolf Widmer1,*
Abstract
There is substantial evidence that stem and progenitor cells secrete trophic factors that have potential for repairing injured
tissues. We have previously reported that the conditioned medium (CM) obtained from endothelial progenitor cells (EPC)
cultures protects striatal neurons against 3-nitropropionic acid-induced toxicity. In the present study we tested the hypothesis
that EPC-CM may support cortical neuronal cell function and/or survival. EPC were isolated from the peripheral blood of healthy
human donors and cultured in hypoxic conditions (1.5% O2) to stimulate the secretion of growth factors. The supernatant or
conditioned medium (EPC-CM) was then collected and used for the various experiments. Primary cultures of cerebral cortex from
fetal rat embryonic day 14 were treated with EPC-CM and challenged by glucose and serum deprivation. We observed that EPC-
CM treatment significantly increased total cell number and cell viability in the cultures. Similarly, the number of lba1-expressing cells
was significantly upregulated by EPC-CM, while western blot analyses for the astroglial marker glial fibrillary acidic protein did not
show a marked difference. Importantly, the number of beta-lll-tubulin-positive neurons in the cultures was significantly augmented
after EPC-CM treatment. Similarly, western blot analyses for beta-III-tubulin showed significant higher signal intensities.
Furthermore, EPC-CM administration protected neurons against glucose- and serum deprivation-induced cell loss.
In sum, our findings identified EPC-CM as a means to promote viability and/or differentiation of cortical neurons and suggest that
EPC-CM might be useful for neurorestorative approaches.
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Introduction
There is growing evidence that stem and progenitor cells
mediate their effects predominantly by secreting trophic fac-
tors. The repertoire of bioactive molecules released in the
extracellular environment is referred as secretome1. The
beneficial effect of secretome has been described for several
pathological conditions including neurodegenerative dis-
eases2. In addition, endothelial progenitor cells (EPC) and
their soluble factors have also been successfully used in trau-
matic brain injury, ischemic stroke, and white matter damage
models3–6. We have recently demonstrated that the condi-
tioned medium of peripheral blood- derived EPC (EPC-CM)
promotes viability of neurons in primary cultures from the
ventral mesencephalic as well as the ganglionic eminence and
importantly, in these cultures EPC-CM elicited neuroprotec-
tive responses against neurotoxic insults induced by 1-methyl-
4-phenyl pyridinium and 3-nitropropionic acid treatment,
respectively7,8.
In the framework of therapeutic applications, secretome-
based applications have the advantage of evoking low immu-
nogenic reactions thus allowing an allogenic use. On the
other hand, in addition to the various beneficial effects
reported, the high variety of active factors present in
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different secretomes may also elicit unwanted side effects,
e.g., cell senescence9. Hence, detailed studies are needed to
understand the current advantages and limitations of
secretome-based treatments for tissue regeneration1. To
explore whether EPC-CM has a wide neuroprotective activ-
ity spectrum, in the present study we investigated the effect
of EPC-CM on differentiating primary cortical progenitor
cells from rat fetuses. In particular, we analyzed whether
EPC-CM might influence the yield and survival of neurons
and attempted to analyze the neuroprotective potential of
EPC-CM against a metabolic insult induced by glucose and
serum deprivation (GSD).
Materials and Methods
Animals
Time pregnant Wistar rats were purchased from Janvier Labs
(Le Genest-Saint-Isle, France) and housed at 12-h light–dark
cycle with food and water ad libitum. All experiments were
carried out in the light phase and in accordance with the
guidelines of the Animal Research Ethics Committee of the
Canton Bern, Switzerland, and the University of Bern Ani-
mal Care and Use Committee, Switzerland (Study No. 6/12,
10/15, and 119/16).
Preparation and Culture of Rat Dissociated
Fetal Cortical Cultures
Cultures of cerebral cortex (CTX) were prepared from
embryonic day 14 (E14) old rat fetuses as described previ-
ously with slight modifications10. In brief, pregnant Wistar
rats were anesthetized using gas inhalation (5% isoflurane,
75% N2O, 20% O2; Peachtree Corners, GA, USA) followed
by an intraperitoneal injection of a mix of ketamine (120 mg/
kg; Vetoquinol AG, Ittigen, Switzerland) and Xylaxine (20
mg/kg; Vetoquinol AG). The fetuses were separated by
cesarean section and the dams immediately thereafter
decapitated and exsanguinated. Then fetuses were eutha-
nized by decapitation and the cortical areas were dissected
bilaterally in cold Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Reinach, Switzerland) according to stan-
dard procedures11. The CTX explants were mechanically
dissociated and plated at a density of 0.3 and 2.0 embryos/
well (seeding density of 700 to 800 viable cells per mm2)
into the 24-well and 6-well plates (Falcon), respectively.
Cell viability, as assessed using the Trypan Blue dye exclu-
sion method in a Neubauer chamber, was always above 65%.
The 24 wells contained glass inserts (glass coverslips of 12
mm diameter, Assistent, Sandheim, Germany). Culture wells
were precoated with poly-L-lysine (0.1 mg/ml; Sigma,
Buchs, Switzerland). The neurons were grown in 0.5 and
2.5 ml, for 24- and 6-well plates, respectively, of standard
culture medium consisting of 55% DMEM, 32.5% Hank’s
balanced salt solution (Gibco), 0.3% glucose, 10% fetal calf
serum (FCS; Gibco), and 1% 0.01 M HEPES (Merck,
Darmstadt, Germany) as well as antibiotics/antimycotics
(061-05240 D; Gibco). The medium was refreshed after 2
days in vitro (DIV) and exchanged at DIV5 to the different
treatment groups, as described below, for another 2 days. At
the end of the experimental period, at DIV7, the cultures
were washed with PBS and processed for the different anal-
yses as described below.
EPC Culture and CM Preparations
EPC were cultivated from peripheral blood mononuclear
cells of healthy human anonymous donors as previously
described12. The buffy coats utilized were purchased from
the Interregional Transfusion Centre of the Swiss Red Cross
(Bern, Switzerland) and no experimental approval or
informed consent was needed. All samples were handled
according to the regulations and guidelines of the University
Hospital Bern, Switzerland. Mononuclear cells were isolated
and plated on fibronectin (Sigma)-coated six-well plastic
dishes (Falcon) in endothelial cell basal medium-2 (EBM-
2; Lonza, Basel, Switzerland) containing endothelial growth
medium BulletKit and 5% FCS (Lonza). To manufacture
EPC-CM, EPC were incubated for 48 h under hypoxic con-
ditions (1.5% O2, 5% CO2, 93.5% N2) using a humidified
gas-sorted anoxic incubator-gloved box (InVivo2 400, Rus-
kinn Technologies, Bridgend, UK) in growth factor-free
EBM-2 containing 1% FCS as previously described13. After
incubation, EPC-CM was collected, sterile filtered, and
snap-frozen until further use13. The EBM-2 was treated in
parallel to the cell cultures and served as control medium
(unconditioned medium).
Treatments
For the immunohistochemical and Western blot analyses the
culture wells were randomly assigned to the different treat-
ment groups and incubated from DIV5 until the end of the
experimental period at DIV7 in EPC-CM or with EBM-2.
We have recently shown that EPC-CM exerted neuropro-
tection for cultured striatal progenitor cells7. Hence, we
assessed whether EPC-CM administration offers a
survival-promoting potential also for cerebral cortical cul-
tures. For that purpose we tested two regimens, i.e., pre- or
posttreatment with EPC-CM. In the pretreatment experi-
ments cultures were either grown in maintenance culture
or EPC-CM supplemented medium up to DIV2 in culture
when they were exposed to a GSD for 2 days as described
previously by Kaneko and co-workers with slight modifica-
tion (solution consisting of 116 mM NaCl, 5.4 mM KCl, 1.8
mM CaCl2, 0.8 mM MgSO4, 1.0 mM Na2HPO4, 0.01 mM
glycine, 26.2 mM NaHCO3, and 10 mM HEPES, pH 7.2)
14.
In the posttreatment experiments cells were after the GSD
consequently grown for additional 2 DIV in the absence or
presence of EPC-CM. Controls were kept in regular main-
tenance medium for the whole experimental period.
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Cell Viability Assay
Cell viability was assessed as previously described with
minor modifications15. Briefly, cultures were treated as
described above. At DIV7 the experimental media were
replaced with incubation medium and the number of viable
cells was assessed by the Presto Blue assay (Invitrogen,
Reinach, Switzerland) using a microplate reader (Ex. 560
nm, Em. 590 nm; VarioSkan, ThermoFisher Scientific, Rein-
ach, Switzerland).
Western Blotting and Protein Measurements
The cells were lysed in RIPA buffer (ThermoFisher Scien-
tific, Reinach, Switzerland) containing protease inhibitor
cocktail set V (Sigma), 10 mM phenylmethylsulfonyl fluor-
ide (Sigma), 1 mM leupeptin (Sigma), and 1 mM sodium
orthovanadate (Sigma). The protein concentration was deter-
mined in two aliquots per lysate using the Pierce BCA Pro-
tein Assay Kit (ThermoFisher Scientific). The Western
blotting was carried out according to the method of
Laemmli16 with some modifications. Equal amounts of the
proteins were run on a 12% polyacrylamide gel and trans-
ferred to a polyvinylidene difluoride membrane (Bio-Rad
Laboratories AG, Cressier, Switzerland). The transfer effi-
ciency was checked by Coomassie Blue staining of the gels.
Blots were blocked for 45 min in 5% fat-free milk powder in
TBS-Tween 0.01% and incubated with the same solution
overnight with primary antibodies [mouse anti-glial fibril-
lary acidic protein (GFAP), 1:500, Millipore, Zug, Switzer-
land; mouse anti-beta-III-tubulin, 1:1,000, Promega,
Dübendorf, Switzerland; mouse anti-microtubule-
associated protein 2 (MAP2), 1: 500, Sigma; rabbit anti-a-
tubulin, 1:2,000, Sigma]. After washing in TBS-Tween
0.01% the blots were incubated for 1 h with antibody-
peroxidase conjugates (anti-mouse or anti-rabbit, 1:10,000;
Jackson ImmunoResearch, Ely, UK) in 5% fat-free milk
powder in TBS-Tween 0.01%. Subsequent to washing the
blots were visualized with the enhanced chemiluminescence
substrate kit (ThermoFisher Scientific) using the Fusion
Pulse TS System (Vilber Lourmat, Collégien, France).
Bands were quantified on 8-bit converted images using the
Fiji software and normalized against a-tubulin. Six cultures
from four independent experiments were included for the
analyses.
Immunocytochemistry
At the end of the experimental period cell cultures were
fixed for 30 min in 4% paraformaldehyde, washed, and
blocked with 10% horse serum in 0.1% Triton-X-100/PBS.
Thereafter, the cells were incubated overnight with the pri-
mary antibodies rabbit anti-GABA (1:5,000; Sigma) in 0.1%
Triton-X-100/PBS with 2.5% horse serum at 4C. Subse-
quent to washes in PBS, the cultures were incubated for 2
h with biotinylated anti-rabbit IgG (1:200, Vector
Laboratories, Servion, Switzerland). Endogenous peroxidase
was blocked for 10 min in 3% hydrogen peroxide and 10%
methanol in PBS. Bound antibodies were visualized after
washes in PBS by the avidin–biotin complex
(VECTASTAIN® ABC-Peroxidase Kit; 1:250, PK-4000;
Vector Laboratories) in combination with the DAB Substrate
Kit (34002, ThermoFischer Scientific). The cultures were
mounted with Aquatex (Millipore, Darmstadt, Germany).
For the analysis of microglial cells and neurons the cul-
tures were treated as described above and incubated over-
night at 4C with the primary antibodies rabbit polyclonal
anti-ionized calcium-binding adapter molecule 1 (Iba-1,
1:1,000, WAKO, Richmond, VA, USA); mouse anti-beta-
III-tubulin (1:1,000, Sigma); Subsequent to washes in PBS,
the cultures were incubated for 2 h with the fluorescently
labeled antibodies Alexa® Fluor donkey anti-rabbit 594 nm
and donkey anti-mouse 488 nm 1:250, Molecular Probes,
Carlsbad, CA, USA). Cultures were then washed for 4 
10 min in PBS and mounted in 0.1 M PBS containing 50%
glycerol.
Histological Analyses
All cultures were analyzed under bright field illumination by a
researcher blinded to the treatment groups as described by our
group before17–20. In brief, only cells with distinct immunor-
eactivity, clear neuronal shape, and visible neurites were
counted as GABA-positive neurons. To obtain cell counts,
5.2% of the glass slide surface (113 mm2) in the culture dish
was analyzed in six areas [in the upper, right, lower, left
corners (distance 2.5 mm from edge) and twice in the center
of the culture; each sized 0.97 mm2] using a 10 objective in
combination with a 10 ocular with counting grid (100
magnification). When doubts about the specification of
GABA-ir neurons existed then the cell cultures were exam-
ined at a higher magnification (400). Fluorescence pictures
stained for beta-lll-tubulin and lba1 were recorded using an
Olympus epifluorescence microscope (BX51, Olympus,
Tokyo, Japan) equipped with a digital camera (Olympus
DP72, Olympus). NeuN-ir cell counts were analyzed in six
areas [in the upper, right, lower, left corners (distance 2.5 mm
from edge) and twice in the center of the culture; each sized
0.15 mm2] using a 20 objective (200 magnification).
Statistical Evaluation
For statistical analysis a commercially available software
package was used (Prism 7.04, GraphPad Software, La Jolla,
CA, USA). To compare group means of several groups, one-
way analysis of variance followed by Tukey’s multiple com-
parison test was used. Statistical significance of two groups
only was assessed by two-tailed unpaired t-test or by the
nonparametric Mann–Whitney test based on the outcome
of the D’Agostino and Pearson normality test. Differences
were considered statistically significant at P <0.05. Data are
presented as mean þ SEM.
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Results
Effects of EPC Conditioned Medium Treatment on
Total Cell Numbers, Viable Cell Numbers, Number of
Microglial Cells, and Levels of GFAP in Dissociated
Cortical Cultures
We first observed that the total cell numbers were signifi-
cantly higher in EPC-CM-treated cultures as compared to
controls (t3.6/12, P < 0.05) (Figure 1A). In line with these
results the cortical cultures treated with EPC-CM disclosed
a significant increase in number of viable cells (t4.4/17, P <
0.05) (Figure 1B). Notably, EPC-CM treatment resulted in a
pronounced and significant increase in number of lba1-ir
cells (t6.5/18, P < 0.05) (Figure 1C) while only a slight
increase in GFAP levels (by 1.2-fold) was found as com-
pared to controls (Figure 1D).
EPC Conditioned Medium Treatment on Number
of Beta-lll-Tubulin-Expressing Neurons and of
Beta-III-Tubulin Levels
The number of beta-III-tubulin-expressing neurons was sig-
nificantly augmented after EPC-CM exposure (t6.5/12,
P < 0.05) (Figure 2A). The percentage of beta-III-tubulin-
positive neurons of total cell numbers as assessed by the
Hoechst staining was significantly higher in the cultures
treated with EPC-CM as compared to controls (by 1.37-
fold, t2.8/12, P < 0.05). In line with this observation, EPC-
CM treatment resulted in a pronounced and significant
increase of beta-III-tubulin levels (t2,7/10, P < 0.05) (Figure
2B). Similarly, we detected significantly higher MAP-2 lev-
els after EPC-CM treatment as compared to controls (by
1.48-fold, t4,7/10, P < 0.05).
EPC-CM Exerts Neuroprotection Against Glucose
and Oxygen Deprivation
We finally investigated whether administration of EPC-
CM prior to or after an insult induced by GSD may have
the potential to rescue GABA-ir neurons from cell loss.
The presence of EPC-CM prior to the insult resulted in a
tendency for higher numbers of surviving GABA-ir cells
[F (2,63) ¼ 28.81; P < 0.05]; however, this difference did
not reach significance (Figure 3A). Notably, administra-
tion of EPC-CM after the insult resulted in significantly
higher numbers of surviving GABA-ir cells [F (2,28) ¼
Fig. 1. Quantitative analysis of number of total cell nuclei (Hoechst, A), viable cell number (B), lba-1-positive cell numbers (C), and Western
blot quantification of GFAP (D) in cerebral cortical cultures. Cultures were grown for 7 DIV and treated without (Ctrl) or with endothelial
progenitor cells secretome (EPC-CM) from DIV5 to DIV7. Data are presented as a percentage of controls and values given as mean þ SEM.
*P < 0.05 versus corresponding control.
DIV: days in vitro; EPC-CM: conditioned medium of peripheral blood-derived endothelial progenitor cells; GFAP: glial fibrillary acidic protein.
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12.17; P < 0.05] even though they did not reach control
levels (Figure 3B).
Discussion
There is mounting evidence that EPC release a wide array of
factors including growth factors, cytokines, lipids, and extra-
cellular matrix, which play a crucial role in supporting tissue
viability and trigger a regenerative response21–23. In fact, the
paracrine actions are believed to be the main mediators for
the therapeutic effect of EPC transplanted in host tis-
sues24,25. The present work showed that EPC-CM treatment
increased total cell numbers as well as overall cell viability
hinting to the idea that EPC-CM treatment targeted a variety
of neuronal and non-neuronal cell populations. Importantly
to note, we demonstrate that EPC-CM exerts important sup-
porting cues on neuronal cells. In particular, we report that
EPC-CM substantially increases the density of mature
neurons as found by immunocytochemical and immunoblot
detection of the specific marker beta-III-tubulin. This notion
is further supported by the higher signal intensity of MAP2,
which is exclusively expressed in perikarya and dendrites of
neurons26. Notably and to our knowledge for the first time,
we could demonstrate that EPC-CM disclosed the capacity
to confer neuroprotection from a metabolic insult. These
results extend our previous observations regarding
survival-promoting capacity of paracrine factors released
by peripheral blood-derived EPC on striatal and ventral
mesencephalic neuronal cells78. The mechanisms and path-
ways involved in higher GABA-ir cell densities found with
EPC-CM supplementation in cultures challenged by GSD,
however, were not addressed in the present study. It is
known that insufficient supply of glucose induces neuronal
cell death as a result of a series of events including activation
of poly(ADP-ribose) polymerase-1, and mitochondrial per-
meability transition, activation of neuronal glutamate
Fig. 2. Representative photomicrographs, quantitative analysis of beta-III-tubulin-positive neurons, and Western blot quantification of beta-
III-tubulin in fetal rat cerebral cortical cultures grown for 7 DIV treated without (Ctrl, open bar) or with endothelial progenitor cells
secretome (EPC-CM, filled bar) from DIV5 to DIV7. Scale bar: 100 mm. Data are presented as a percentage of controls and values given as
mean þ SEM. *P < 0.05.
DIV: days in vitro; EPC-CM: conditioned medium of peripheral blood-derived endothelial progenitor cells.
Fig. 3. Quantitative analysis of GABA-ir cell densities in cerebral cortical cultures fetal cultures in a pretreatment and posttreatment
regimen. Cultures were grown for 7 DIV. GSD was performed from DIV2 to DIV4. Cultures were exposed to EPC-CM either from DIV0 to
DIV2 (EPC-CM and GSD) or from DIV4 to DIV6 (GSD and EPC-CM). Untreated cultures served as controls (Ctrl). Data are presented as a
percentage of controls and values are given as mean þ SEM. *P < 0.05 versus control; #P < 0.05 versus GSD-treated cultures.
DIV: days in vitro; EPC-CM: conditioned medium of peripheral blood-derived endothelial progenitor cells; GSD: glucose and serum
deprivation.
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receptors, and production of reactive oxygen species27. Find-
ings from our earlier reports suggest that cell viability sup-
ported by EPC-CM may be due to a raise in the antioxidant
capacity of the cell28. Moreover, it can be hypothesized that
EPC-CM supports the bioenergetic homeostasis as it is
known that developing cortical neurons’ functionality in in
vitro systems is deeply influenced by the metabolic
microenvironment29.
The identification of the factors for the survival
improvement of neuronal progenitors was not specifically
addressed in our paper. However, our earlier study identi-
fied lipidic factors as important mediators of the actions of
EPC-CM7. Moreover, we have previously shown that EPC-
CM contains a number of neurotrophic factors including
brain-derived neurotrophic factor glial cell line-derived
neurotrophic factor, neuritin, and vascular endothelial
growth factor, which are critical for the developing cerebral
cortex8,30. In addition, it has been reported that EPC secre-
tome has the capacity to promote oligodendrocyte expan-
sion and maturation in mice in a model of cerebral
hypoperfusion6. Similar to our earlier observations, in the
present study EPC-CM did not display significant effects
on astrocytes hinting to the idea that this cell type is not a
major target of the EPC-CM-mediated actions. Although it
is difficult to compare findings gathered from different
culture systems, it is interesting to note that we did not find
any newly generated neurons in ventral mesencephalic cul-
tures following EPC-CM treatment8. Further experiments
will be needed to verify whether EPC-CM promotes the
proliferation of immature neurons in cortical cultures and
to evaluate the possible role of lipids and other factors. On
the other hand, the finding that EPC-CM induced a promi-
nent increase of microglia cell numbers was not surprising
and in line with our past report7. In fact, we have previously
reported that several immunomodulatory cytokines are
secreted from EPC7,8. It is thus reasonable to speculate that
the effects of EPC-CM on cortical neurons are the result of
the direct action of neurotrophic factors found in EPC
secretome but also influenced by the complex network of
signaling cross-talk between the different cell types present
in the cortical cultures. In this context, the definition of the
actual impact of microglia activation would improve the
understanding of the mechanisms of action of EPC-CM and
eventually further improve the tissue regenerative capacity
of EPC-CM.
In sum, the present study broadens the current knowledge
of the tissue-protective and -regenerative potential of EPC-
CM by demonstrating the supportive activity of EPC secre-
tome against GSD-induced neuronal degeneration in vitro.
These novel findings thus highlight the potential of EPC-CM
to conceive strategies to promote neuronal viability. It can be
prospected that EPC-CM might contribute to the future
development of new approaches for neurorestorative thera-
peutic paradigms alternative or complementary to cell
transplantation.
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